Media Summary: Organized by Instituted for Clinical Research, MOH Malaysia Slide presentation: Introduction and Malaysia's Experience in Phase ... Alex Luedtke, Ph.D. This presentation is part of the DESIGN APPROACHES FOR CURRENT AND FUTURE HIV PREVENTION ... In this presentation, Eugene Ruzagira (MBChB, MPH, PhD) outlines the protocol of the Multi Arms Multi Steps (MAMS)

S3 01 Prepvacc Trial Statistical - Detailed Analysis & Overview

Organized by Instituted for Clinical Research, MOH Malaysia Slide presentation: Introduction and Malaysia's Experience in Phase ... Alex Luedtke, Ph.D. This presentation is part of the DESIGN APPROACHES FOR CURRENT AND FUTURE HIV PREVENTION ... In this presentation, Eugene Ruzagira (MBChB, MPH, PhD) outlines the protocol of the Multi Arms Multi Steps (MAMS) Despite 40 years of research the HIV epidemic remains a significant global health challenge and an HIV vaccine is still elusive. Former U.S. Rep. Michael C. Burgess, MD, (R-TX) warns that damaging the foundations of the vaccine safety net will bring back ... From Young Investigator and Research Community Perspectives Host: This symposium was co-developed with the CHVI ...

Attorney Richard Kingham explains how research and development, the Vaccine Injury Compensation Program (VICP), and ... Curious about how vaccines were developed and approved? Through the ACTIV program, NIH is working with many ... The first panel of the virtual workshop aims to reflect on current Lawrence Corey, Fred Hutchinson Cancer Research Center, United States presents the results of the Antibody Mediated ...

Photo Gallery

S3-01 PrEPVacc trial statistical analysis plan
PrEPVacc: An in-depth look at the trial, and what’s next
S3E1 - Introduction to Phase 1 Trial & COVID-19 vaccine trial experience sharing
S3-03: Estimation of Dapivirine vaginal ring efficacy in the HOPE trial
S1-07: PrEPVacc concepts - Registrational cohort and prequalification period (Eugene Ruzagira)
RWCC Day 1: Case-Based Approaches to Pre- and Post-Exposure Prophylaxis
Lynn Morris - HIV prevention: antibodies and vaccine development
What Happens When You Undermine the Vaccine System
CAHR2017 Special Session Future of Canadian HIV Vaccine Research - Part 1
Why Every Piece of the Vaccine System Has to Stay Intact
What is a Phase 3 Clinical Trial for a Vaccine Candidate?
VE Panel 1: Design approaches for current and future HIV prevention efficacy trials
View Detailed Profile
S3-01 PrEPVacc trial statistical analysis plan

S3-01 PrEPVacc trial statistical analysis plan

A brief overview of the

PrEPVacc: An in-depth look at the trial, and what’s next

PrEPVacc: An in-depth look at the trial, and what’s next

Join the

S3E1 - Introduction to Phase 1 Trial & COVID-19 vaccine trial experience sharing

S3E1 - Introduction to Phase 1 Trial & COVID-19 vaccine trial experience sharing

Organized by Instituted for Clinical Research, MOH Malaysia Slide presentation: Introduction and Malaysia's Experience in Phase ...

S3-03: Estimation of Dapivirine vaginal ring efficacy in the HOPE trial

S3-03: Estimation of Dapivirine vaginal ring efficacy in the HOPE trial

Alex Luedtke, Ph.D. This presentation is part of the DESIGN APPROACHES FOR CURRENT AND FUTURE HIV PREVENTION ...

S1-07: PrEPVacc concepts - Registrational cohort and prequalification period (Eugene Ruzagira)

S1-07: PrEPVacc concepts - Registrational cohort and prequalification period (Eugene Ruzagira)

In this presentation, Eugene Ruzagira (MBChB, MPH, PhD) outlines the protocol of the Multi Arms Multi Steps (MAMS)

RWCC Day 1: Case-Based Approaches to Pre- and Post-Exposure Prophylaxis

RWCC Day 1: Case-Based Approaches to Pre- and Post-Exposure Prophylaxis

Presenter: Hyman Scott, MD, MPH.

Lynn Morris - HIV prevention: antibodies and vaccine development

Lynn Morris - HIV prevention: antibodies and vaccine development

Despite 40 years of research the HIV epidemic remains a significant global health challenge and an HIV vaccine is still elusive.

What Happens When You Undermine the Vaccine System

What Happens When You Undermine the Vaccine System

Former U.S. Rep. Michael C. Burgess, MD, (R-TX) warns that damaging the foundations of the vaccine safety net will bring back ...

CAHR2017 Special Session Future of Canadian HIV Vaccine Research - Part 1

CAHR2017 Special Session Future of Canadian HIV Vaccine Research - Part 1

From Young Investigator and Research Community Perspectives Host: This symposium was co-developed with the CHVI ...

Why Every Piece of the Vaccine System Has to Stay Intact

Why Every Piece of the Vaccine System Has to Stay Intact

Attorney Richard Kingham explains how research and development, the Vaccine Injury Compensation Program (VICP), and ...

What is a Phase 3 Clinical Trial for a Vaccine Candidate?

What is a Phase 3 Clinical Trial for a Vaccine Candidate?

Curious about how #COVID19 vaccines were developed and approved? Through the ACTIV program, NIH is working with many ...

VE Panel 1: Design approaches for current and future HIV prevention efficacy trials

VE Panel 1: Design approaches for current and future HIV prevention efficacy trials

The first panel of the virtual workshop aims to reflect on current

S2-07: VRC01 antibody prevention of HIV

S2-07: VRC01 antibody prevention of HIV

Lawrence Corey, Fred Hutchinson Cancer Research Center, United States presents the results of the Antibody Mediated ...